Clinical Trials

1,210 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06498635 2026-05-27

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

306 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

11 enrolled

Phase EARLY_PHASE1 Recruiting

Urinary Bladder Neoplasms

NCT03594630 2026-05-20

Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer

120 enrolled

Rectal Neoplasms

NCT02954874 2026-05-15

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

1,155 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05255653 2026-05-15

RAINBO

Phase 2/3 Recruiting

1,615 enrolled

Endometrial Neoplasms

NCT06733350 2026-05-14

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Phase 4 Recruiting

600 enrolled

Phase NA Active not recruiting

Prostatic Neoplasms

NCT02194738 2026-05-13

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

8,300 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02595944 2026-05-13

ANVIL

903 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03233711 2026-05-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

344 enrolled

Anal Canal Carcinoma, Anus Neoplasms

NCT03244384 2026-05-13

AMBASSADOR

739 enrolled

Ureteral Neoplasms

NCT03811015 2026-05-13

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

636 enrolled

Phase 3 Not yet recruiting

Oropharyngeal Neoplasms

NCT07388524 2026-05-13

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

336 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05541016 2026-05-12

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

455 enrolled

Carcinoma, Oropharyngeal Neoplasms

NCT05640999 2026-05-12

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

393 enrolled

Endometrial Neoplasms

NCT05812807 2026-05-08

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

1,295 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT03180268 2026-05-07

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

163 enrolled

CNS

Meningioma

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

484 enrolled

Breast Neoplasms

NCT02176967 2026-05-05

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

621 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT06401330 2026-05-05

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

1,656 enrolled

Stage I Mixed Cell Type Kidney Wilms Tumor

NCT06647953 2026-05-05

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

110 enrolled

Pleuropulmonary blastoma

NCT02193282 2026-05-04

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

390 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03055013 2026-05-04

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

819 enrolled 12 charts

Carcinoma, Renal Cell

NCT06745024 2026-05-04

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

280 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06958328 2026-05-04

LAP100

356 enrolled

Pancreatic Neoplasms

NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

226 enrolled 16 charts

Plasma cell

Smoldering Multiple Myeloma

NCT03737981 2026-05-01

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

465 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01096368 2026-04-30

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Phase 3 Completed

479 enrolled 24 charts

Ependymoma

NCT01251861 2026-04-29

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

108 enrolled 16 charts

Phase 1 Not yet recruiting

Prostatic Neoplasms

NCT06743555 2026-04-28

SAVED LUNG

14 enrolled

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT06378866 2026-04-20

DIVINE

532 enrolled

Prostatic Neoplasms

NCT07405476 2026-04-17

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

38 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06539468 2026-04-14

Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients

Phase NA Recruiting

200 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT01244789 2026-04-13

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

244 enrolled

Endometrial Neoplasms

NCT02275533 2026-04-13

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

Other hematologic neoplasm

82 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT07513324 2026-04-07

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Phase 2 Not yet recruiting

116 enrolled

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05873608 2026-04-06

Communication Issues in Patient and Provider Discussions of Immunotherapy

Phase NA Recruiting

125 enrolled

Other solid neoplasm

Hematopoietic and Lymphoid System Neoplasm

NCT07472478 2026-03-16

GIVEN

32 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

1,150 enrolled 6 charts

Dermatologic

Melanoma

NCT06378346 2026-02-23

GU-01

60 enrolled

Phase 4 Not yet recruiting

Prostatic Neoplasms

NCT07281547 2026-02-18

Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain

25 enrolled

Endometrial Neoplasms

NCT03516617 2026-02-09

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

LymphoidOther hematologic neoplasm

120 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03059485 2026-02-04

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

Other hematologic neoplasm

82 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT05633615 2026-02-02

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

396 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05894083 2026-02-02

A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)

150 enrolled

Phase NA Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT02492607 2026-01-26

LORD

2,500 enrolled

Phase EARLY_PHASE1 Recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT07025226 2026-01-26

Senolytics

10 enrolled

CNS

Glioma

NCT02870907 2026-01-07

RB SFCE 09

195 enrolled

Other solid neoplasm

Retinoblastoma

NCT05717166 2025-12-31

SABR-SYNC